|
|
|
51-200 employees
View all
|
|
pharmaceuticals
|
|
Rapsgatan 7,Fyrislund,Uppsala County,SE
|
|
Orexo develops improved pharmaceuticals and digital therapies addressing unmet needs mainly within the growing space of mental illness and substance use disorder. The products are commercialized by Orexo in the US or via partners worldwide. The main market today is the American market for buprenorphine/naloxone products, where Orexo commercializes its lead product ZUBSOLVĀ® for treatment of opioid use disorder. Total net sales for 2019 amounted to SEK 845 million and the number of employees was 127. Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) and is available as ADRs on OTCQX (ORXOY) in the US. The company is headquartered in Uppsala, Sweden, where research and development activities are performed.For more information about Orexo please visit, www.orexo.com. You can also follow Orexo on Twitter, @orexoabpubl, LinkedIn and YouTube.
|
Orexo AB publ Email Formats | Example Email Formats | Percentage |
---|---|---|
{first}.{last} | [email protected] |
100%
|
The widely used Orexo AB publ email format is {first}.{last} (e.g. [email protected]) with 100% adoption across the company.
To contact Orexo AB publ customer service number in your country click here to find.
Nikolaj Sorensen is the CEO of Orexo AB publ. To contact Nikolaj Sorensen email at [email protected].
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.